EHA 2021: key trial updates in myeloma

The treatment and management of multiple myeloma has evolved drastically over the last ten years with the introduction of many novel drug classes and therapies, resulting in notable improvements in overall survival. However, many patients remain relapsed or refractory and thus clinical trials of novel agents and combinations are key to improving the outcomes of high-risk subgroups. In particular, there has been a rapid increase in the number of immunotherapies being trialled for myeloma patients, including monoclonal antibody and chimeric antigen receptor T-cell (CAR-T) therapies.

In this podcast, Saad Usmani, MD, MBBS, MBA, from the Levine Cancer Institute and Atrium Health, Charlotte, NC, Maria-Victoria Mateos, MD, PhD, from the University of Salamanca, Salamanca, Spain, Enrique M. Ocio, MD, PhD, from the Marqués de Valdecilla University Hospital, Santander, Spain, Amrita Krishnan, MD, from City of Hope, Duarte, CA, and Evangelos Terpos, MD, PhD, from the National and Kapodistrian University of Athens, Athens, Greece, share key updates on clinical trials of novel therapies and regimens for the treatment of multiple myeloma, as presented at this year’s Congress of the European Hematology Association (EHA 2021).